9.08
price down icon0.44%   -0.04
after-market After Hours: 9.06 -0.02 -0.22%
loading
Sage Therapeutics Inc stock is traded at $9.08, with a volume of 842.69K. It is down -0.44% in the last 24 hours and up +40.56% over the past month. Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$9.12
Open:
$9.07
24h Volume:
842.69K
Relative Volume:
0.59
Market Cap:
$437.72M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-1.0822
EPS:
-8.39
Net Cash Flow:
$-424.74M
1W Performance:
-1.52%
1M Performance:
+40.56%
6M Performance:
+67.22%
1Y Performance:
-17.68%
1-Day Range:
Value
$9.05
$9.13
1-Week Range:
Value
$9.04
$9.295
52-Week Range:
Value
$4.62
$13.47

Sage Therapeutics Inc Stock (SAGE) Company Profile

Name
Name
Sage Therapeutics Inc
Name
Phone
617-299-8380
Name
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Employee
487
Name
Twitter
@SageBiotech
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
SAGE's Discussions on Twitter

Compare SAGE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SAGE
Sage Therapeutics Inc
9.08 437.72M 91.06M -503.14M -424.74M -8.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-11-25 Resumed BofA Securities Underperform
Nov-21-24 Upgrade RBC Capital Mkts Underperform → Sector Perform
Oct-10-24 Resumed Raymond James Mkt Perform
Oct-04-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-30-24 Downgrade TD Cowen Buy → Hold
Jul-25-24 Downgrade JP Morgan Overweight → Neutral
May-29-24 Initiated Citigroup Sell
May-29-24 Initiated Robert W. Baird Neutral
Apr-17-24 Downgrade BofA Securities Neutral → Underperform
Dec-12-23 Initiated Deutsche Bank Hold
Aug-08-23 Downgrade Canaccord Genuity Buy → Hold
Aug-08-23 Downgrade Goldman Buy → Neutral
Aug-08-23 Downgrade Needham Buy → Hold
Aug-07-23 Downgrade BofA Securities Buy → Neutral
Aug-07-23 Downgrade Oppenheimer Outperform → Perform
Aug-07-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-07-23 Downgrade Stifel Buy → Hold
Aug-07-23 Downgrade Wedbush Outperform → Neutral
Jul-27-23 Initiated Scotiabank Sector Outperform
Mar-13-23 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jan-03-23 Downgrade Guggenheim Buy → Neutral
Nov-01-22 Initiated Loop Capital Hold
Mar-31-22 Initiated Berenberg Hold
Nov-02-21 Upgrade Guggenheim Neutral → Buy
Oct-19-21 Resumed Morgan Stanley Equal-Weight
Oct-07-21 Downgrade Jefferies Buy → Hold
Sep-23-21 Initiated Needham Buy
Jun-16-21 Downgrade Citigroup Buy → Neutral
Apr-07-21 Initiated Piper Sandler Overweight
Feb-26-21 Downgrade Mizuho Buy → Neutral
Feb-25-21 Reiterated H.C. Wainwright Neutral
Feb-02-21 Resumed Raymond James Mkt Perform
Jan-22-21 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Jan-04-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-04-20 Upgrade Mizuho Neutral → Buy
Dec-01-20 Downgrade Raymond James Outperform → Mkt Perform
Nov-16-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-06-20 Reiterated H.C. Wainwright Neutral
Sep-11-20 Upgrade Wedbush Neutral → Outperform
Aug-10-20 Upgrade Raymond James Mkt Perform → Outperform
May-08-20 Downgrade Wedbush Outperform → Neutral
Apr-08-20 Downgrade Guggenheim Buy → Neutral
Mar-18-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-28-20 Reiterated H.C. Wainwright Neutral
Feb-06-20 Initiated Mizuho Neutral
Dec-06-19 Reiterated RBC Capital Mkts Outperform
Dec-05-19 Reiterated Guggenheim Buy
Dec-05-19 Downgrade SunTrust Buy → Hold
Oct-30-19 Initiated H.C. Wainwright Neutral
May-23-19 Initiated Wedbush Outperform
Apr-25-19 Initiated Jefferies Buy
Dec-14-18 Initiated Wolfe Research Outperform
Oct-11-18 Initiated Oppenheimer Outperform
View All

Sage Therapeutics Inc Stock (SAGE) Latest News

pulisher
Jun 18, 2025

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire Sage Therapeutics stock for $8.50 per share - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire depression drugmaker Sage - MSN

Jun 18, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Update: Truist Securities Raises Price Target | SAGE - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE: HC Wainwright Maintains Neutral Rating and $12 Price Target | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Rating Maintained as Price Target is Raised by Canacc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Price Target Raised Amid Acquisition News | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone - Benzinga

Jun 17, 2025
pulisher
Jun 16, 2025

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com

Jun 16, 2025
pulisher
Jun 16, 2025

Piper Sandler Downgrades Sage Therapeutics (SAGE) Following Acqu - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald

Jun 16, 2025
pulisher
Jun 16, 2025

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus’ $795 million bid sufficient for Sage - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics By Stocktwits - Investing.com India

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to buy Sage for up to $795 million - Axios

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Explodes Over 35% in Massive Rally on Nasdaq - Daily Chhattisgarh News

Jun 16, 2025
pulisher
Jun 16, 2025

Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Rating Reiterated as Hold by Needham | SAGE Stock New - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus

Jun 16, 2025

Sage Therapeutics Inc Stock (SAGE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Cap:     |  Volume (24h):